BDKRB2 and hereditary angioedema: Results of an open‐label, phase 3 study of icatibant reported efficacy and tolerability of this bradykinin B2 receptor antagonist for acute treatment of C1‐INH‐HAE in pediatric patients (inclusion criteria, aged 2‐17 years).31 However, icatibant is only indicated as acute treatment in adults.